Research Article

Patient’s perception of the benefits of long-term opioids: Reinforcement associated with short-term effects

James P Robinson*

Published: 03 May, 2023 | Volume 7 - Issue 1 | Pages: 008-011

The appropriateness of opioid therapy for patients with Chronic Non-Malignant Pain (CNCP) has been questioned by a variety of researchers and policy makers [1-3]. One comprehensive review concluded that the benefits of such therapy for pain relief and functional improvement are modest at best and that opioid therapy is associated with significant harms including various symptoms (e.g., headache, nausea, sedation), development of opioid use disorder, fractures and death from overdose [3].

Read Full Article HTML DOI: 10.29328/journal.jatr.1001026 Cite this Article Read Full Article PDF


  1. Agency Medical Directors’ Group. 2015 Opioid Dosing Guideline. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf
  2. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1. PMID: 36327391; PMCID: PMC9639433.
  3. Chou R, Hartung D, Turner J, Blazina I, Chan B, Levander X, McDonagh M, Selph S, Fu R, Pappas M. Opioid Treatments for Chronic Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. Report No.: 20-EHC011. PMID: 32338848.
  4. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007 Mar 9;8:27. doi: 10.1186/1471-2474-8-27. PMID: 17349056; PMCID: PMC1829161.
  5. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain. 2010 Jan;14(1):5-10. doi: 10.1016/j.ejpain.2009.01.006. Epub 2009 Mar 4. PMID: 19264521.
  6. Vallerand A, Nowak L. Chronic opioid therapy for nonmalignant pain: the patient's perspective. Part I--life before and after opioid therapy. Pain Manag Nurs. 2009 Sep;10(3):165-72. doi: 10.1016/j.pmn.2009.03.007. PMID: 19706354.
  7. Vallerand A, Nowak L. Chronic opioid therapy for nonmalignant pain: the patient's perspective. Part II--Barriers to chronic opioid therapy. Pain Manag Nurs. 2010 Jun;11(2):126-31. doi: 10.1016/j.pmn.2009.03.006. Epub 2010 Apr 22. PMID: 20510843.
  8. Blake S, Ruel B, Seamark C, Seamark D. Experiences of patients requiring strong opioid drugs for chronic non-cancer pain: a patient-initiated study. Br J Gen Pract. 2007 Feb;57(535):101-8. PMID: 17263926; PMCID: PMC2034169.
  9. Hulen E, Saha S, Morasco BJ, Zeigler C, Mackey K, Edwards ST. Sources of Distress in Primary Care Opioid Management and the Role of a Controlled Substance Review Group: A Qualitative Study. Pain Med. 2018 Aug 1;19(8):1570-1577. doi: 10.1093/pm/pnx259. PMID: 29099982.
  10. Kennedy LC, Binswanger IA, Mueller SR, Levy C, Matlock DD, Calcaterra SL, Koester S, Frank JW. "Those Conversations in My Experience Don't Go Well": A Qualitative Study of Primary Care Provider Experiences Tapering Long-term Opioid Medications. Pain Med. 2018 Nov 1;19(11):2201-2211. doi: 10.1093/pm/pnx276. PMID: 29126138; PMCID: PMC6454789.
  11. Matthias MS, Johnson NL, Shields CG, Bair MJ, MacKie P, Huffman M, Alexander SC. "I'm Not Gonna Pull the Rug out From Under You": Patient-Provider Communication About Opioid Tapering. J Pain. 2017 Nov;18(11):1365-1373. doi: 10.1016/j.jpain.2017.06.008. Epub 2017 Jul 8. PMID: 28690000; PMCID: PMC6219456.
  12. Sullivan MD, Von Korff M, Banta-Green C, Merrill JO, Saunders K. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010 May;149(2):345-353. doi: 10.1016/j.pain.2010.02.037. Epub 2010 Mar 23. PMID: 20334974; PMCID: PMC3318978.
  13. Watson CP, Watt-Watson J, Chipman M. The long-term safety and efficacy of opioids: a survey of 84 selected patients with intractable chronic noncancer pain. Pain Res Manag. 2010 Jul-Aug;15(4):213-7. doi: 10.1155/2010/867201. PMID: 20808965; PMCID: PMC2935720.
  14. Robinson JP, Dansie EJ, Wilson HD, Rapp S, Turk DC. Attitudes and Beliefs of Working and Work-Disabled People with Chronic Pain Prescribed Long-Term Opioids. Pain Med. 2015 Jul;16(7):1311-24. doi: 10.1111/pme.12770. Epub 2015 Apr 30. PMID: 25929427.
  15. Ballantyne JC, Sullivan MD, Kolodny A. Opioid Dependence vs Addiction: A Distinction Without a Difference? Arch Intern Med. 2012 Sep 24;172(17):1342-3. doi: 10.1001/archinternmed.2012.3212. PMID: 22892799.
  16. Cofer CN, Appley MH. Motivation: Theory and research. New York: Wiley. 1964.
  17. Fields SA, Lange K, Ramos A, Thamotharan S, Rassu F. The relationship between stress and delay discounting: a meta-analytic review. Behav Pharmacol. 2014 Sep;25(5-6):434-44. doi: 10.1097/FBP.0000000000000044. PMID: 25089842.
  18. Rounds JS, Beck JG, Grant DM. Is the delay discounting paradigm useful in understanding social anxiety? Behav Res Ther. 2007 Apr;45(4):729-35. doi: 10.1016/j.brat.2006.06.007. Epub 2006 Aug 7. PMID: 16890909.
  19. Takahashi T, Oono H, Inoue T, Boku S, Kako Y, Kitaichi Y, Kusumi I, Masui T, Nakagawa S, Suzuki K, Tanaka T, Koyama T, Radford MH. Depressive patients are more impulsive and inconsistent in intertemporal choice behavior for monetary gain and loss than healthy subjects--an analysis based on Tsallis' statistics. Neuro Endocrinol Lett. 2008 Jun;29(3):351-8. PMID: 18580849.
  20. Mani A, Mullainathan S, Shafir E, Zhao J. Poverty impedes cognitive function. Science. 2013 Aug 30;341(6149):976-80. doi: 10.1126/science.1238041. PMID: 23990553.
  21. Kimura K, Izawa S, Sugaya N, Ogawa N, Yamada KC, Shirotsuki K, Mikami I, Hirata K, Nagano Y, Hasegawa T. The biological effects of acute psychosocial stress on delay discounting. Psychoneuroendocrinology. 2013 Oct;38(10):2300-8. doi: 10.1016/j.psyneuen.2013.04.019. Epub 2013 Jun 12. PMID: 23768971.
  22. Webster LR, Slevin KA, Narayana A, Earl CQ, Yang R. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013 Sep;14(9):1332-45. doi: 10.1111/pme.12184. Epub 2013 Jul 15. PMID: 23855816.
  23. Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011 Mar;112(3):693-702. doi: 10.1213/ANE.0b013e318209d320. Epub 2011 Feb 8. PMID: 21304148.
  24. Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D, Fallon M. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage. 2011 Feb;41(2):358-66. doi: 10.1016/j.jpainsymman.2010.11.004. PMID: 21334555.
  25. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Apr;29(4):588-601. doi: 10.1016/j.clinthera.2007.04.007. PMID: 17617282.
  26. Zacny JP, Drum M. Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex. Drug Alcohol Depend. 2010 Mar 1;107(2-3):209-14. doi: 10.1016/j.drugalcdep.2009.10.012. Epub 2009 Nov 30. PMID: 19948383; PMCID: PMC2822039.
  27. Zacny JP, Paice JA, Coalson DW. Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers. Drug Alcohol Depend. 2012 Aug 1;124(3):274-82. doi: 10.1016/j.drugalcdep.2012.01.023. Epub 2012 Feb 25. PMID: 22365897; PMCID: PMC3568773.
  28. Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Psychopharmacology (Berl). 2011 Dec;218(3):471-81. doi: 10.1007/s00213-011-2349-6. Epub 2011 May 21. PMID: 21603891.
  29. Zacny JP, Gutierrez S, Kirulus K, McCracken SG. Psychopharmacological effects of oxycodone in volunteers with and without generalized anxiety disorder. Exp Clin Psychopharmacol. 2011 Apr;19(2):85-94. doi: 10.1037/a0022952. PMID: 21463065.
  30. Schmidt A, Denier N, Magon S, Radue EW, Huber CG, Riecher-Rossler A, Wiesbeck GA, Lang UE, Borgwardt S, Walter M. Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution. Transl Psychiatry. 2015 Mar 24;5(3):e533. doi: 10.1038/tp.2015.28. PMID: 25803496; PMCID: PMC4354356.
  31. Walter M, Denier N, Gerber H, Schmid O, Lanz C, Brenneisen R, Riecher-Rössler A, Wiesbeck GA, Scheffler K, Seifritz E, McGuire P, Fusar-Poli P, Borgwardt S. Orbitofrontal response to drug-related stimuli after heroin administration. Addict Biol. 2015 May;20(3):570-9. doi: 10.1111/adb.12145. Epub 2014 Apr 11. PMID: 24720731.
  32. Schmidt A, Borgwardt S, Gerber H, Wiesbeck GA, Schmid O, Riecher-Rössler A, Smieskova R, Lang UE, Walter M. Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. Biol Psychiatry. 2014 Aug 15;76(4):289-96. doi: 10.1016/j.biopsych.2013.10.019. Epub 2013 Nov 4. PMID: 24314348.
  33. Blum J, Gerber H, Gerhard U, Schmid O, Petitjean S, Riecher-Rössler A, Wiesbeck GA, Borgwardt SJ, Walter M. Acute effects of heroin on emotions in heroin-dependent patients. Am J Addict. 2013 Nov-Dec;22(6):598-604. doi: 10.1111/j.1521-0391.2013.12025.x. Epub 2013 Apr 11. PMID: 24131168.
  34. Greenwald MK, Hursh SR. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: effects of unit price and pre-session drug supply. Drug Alcohol Depend. 2006 Oct 15;85(1):35-48. doi: 10.1016/j.drugalcdep.2006.03.007. Epub 2006 Apr 17. PMID: 16616994.
  35. Greenwald MK. Opioid craving and seeking behavior in physically dependent volunteers: effects of acute withdrawal and drug reinforcement opportunity. Exp Clin Psychopharmacol. 2005 Feb;13(1):3-14. doi: 10.1037/1064-1297.13.1.3. PMID: 15727498.
  36. Mackillop J, Murphy JG, Tidey JW, Kahler CW, Ray LA, Bickel WK. Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology (Berl). 2009 Mar;203(1):33-40. doi: 10.1007/s00213-008-1367-5. Epub 2008 Oct 17. PMID: 18925387; PMCID: PMC2774887.
  37. Johnson MW, Bickel WK. Replacing relative reinforcing efficacy with behavioral economic demand curves. J Exp Anal Behav. 2006 Jan;85(1):73-93. doi: 10.1901/jeab.2006.102-04. PMID: 16602377; PMCID: PMC1397796.
  38. Jacobs EA, Bickel WK. Modeling drug consumption in the clinic using simulation procedures: demand for heroin and cigarettes in opioid-dependent outpatients. Exp Clin Psychopharmacol. 1999 Nov;7(4):412-26. doi: 10.1037//1064-1297.7.4.412. PMID: 10609976.


Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?